Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
ilorasertib(一种双重 Aurora/VEGF 受体激酶抑制剂)治疗血液系统恶性肿瘤患者的 1 期剂量递增试验
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-015-0242-6
Garcia-Manero, Guillermo; Tibes, Raoul; Kadia, Tapan; Kantarjian, Hagop; Arellano, Martha; Knight, Emily A; Xiong, Hao; Qin, Qin; Munasinghe, Wijith; Roberts-Rapp, Lisa; Ansell, Peter; Albert, Daniel H; Oliver, Brian; McKee, Mark D; Ricker, Justin L; Khoury, Hanna Jean